Physician profile

Amanda L Witt

Neuromuscular Medicine (Physical Medicine & Rehabilitation) · Jackson, MS

NPI 1386840619

$46,727.12

in general payments reported to CMS, 2019-2025

44 companies · $1,262 in 2025

The $1,262 reported for 2025 was more than what 81% of Neuromuscular Medicine (Physical Medicine & Rehabilitation) providers received nationally (typical 2025 total: $128).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$2,758.75
Education$51.89

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Biogen, INC. $41,994.07 2019-2025 Spinraza, Skyclarys, Qalsody
Csl Behring $932.98 2019-2025 Hizentra
Alexion Pharmaceuticals, INC. $923.32 2019-2025 Ultomiris
Ucb, INC. $429.35 2020-2025 Rystiggo, Zilbrysq, Fintepla
Argenx US, INC. $159.44 2023-2025 Vyvgart, Vyvgart Hytrulo
Itf Therapeutics LLC $158.72 2024-2025
Piramal Critical Care $133.75 2019-2025
Catalyst Pharmaceuticals, INC. $131.69 2024-2025
Allergan, INC. $122.97 2019-2022
Tanabe Pharma America, INC. $118.65 2019-2023
Teva Pharmaceuticals USA, INC. $111.64 2020-2022
Strongbridge US INC. $103.21 2019-2020
Amylyx Pharmaceuticals, INC. $100.71 2023-2024 Relyvrio
Abbvie INC. $95.51 2023-2025 Botox
Sarepta Therapeutics, INC. $86.83 2023-2025 Elevidys
Show all 44 companies
CompanyGeneral paymentsYearsTop products
Grifols USA, LLC $85.89 2019-2020
Takeda Pharmaceuticals U.S.A., INC. $84.73 2023-2025 Hyqvia, Gammagard
Natus Medical Incorporated $83.00 2022
Avanir Pharmaceuticals, INC. $81.20 2019-2022
Otsuka America Pharmaceutical, INC. $77.15 2023 Nuedexta
Janssen Pharmaceuticals, INC $75.78 2022-2023 Ponvory
Biohaven Pharmaceutical Holding Company Ltd. $65.94 2022
Akcea Therapeutics, INC. $62.38 2019-2020
Dynasplint Systems INC. $45.77 2022
Emd Serono, INC. $44.57 2022-2023 Mavenclad
Eisai INC. $40.09 2021-2022
Amicus Therapeutics, INC. $38.37 2024-2025 Galafold
Alnylam Pharmaceuticals INC. $35.05 2022-2023 Onpattro
Acadia Pharmaceuticals INC $34.82 2022-2023 Nuplazid
Neurocrine Biosciences, INC. $32.28 2021-2022
Sunovion Pharmaceuticals INC. $31.12 2019-2020
Genentech USA, INC. $23.68 2020
Zimmer Biomet Holdings, INC. $22.97 2024 Rosa
Janssen Biotech, INC. $17.45 2025
Ge Healthcare $16.63 2022
Xeris Pharmaceuticals, INC. $16.21 2021
Astrazeneca Pharmaceuticals Lp $15.48 2024 Wainua
Pfizer INC. $15.11 2023
Genzyme Corporation $14.79 2022
Acorda Therapeutics, INC $14.67 2023 Inbrija
Upsher-Smith Laboratories LLC $13.19 2020
Biohaven Pharmaceuticals, INC. $12.57 2021
Portola Pharmaceuticals, LLC $11.85 2019
Supernus Pharmaceuticals, INC. $11.54 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Amanda L Witt

$46,727.12

in general payments reported 2019-2025

Years
2019-2025
Top company
Biogen, INC.
Context
The $1,262 reported for 2025 was more than what 81% of Neuromuscular Medicine (Physical Medicine & Rehabilitation) providers received nationally (typical 2025 total: $128).

https://glasscript.com/doctor/63178/amanda-l-witt

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.